Showing results (251-260 of 318) with videos related to

Sort By:
Pageof 32
JTO Clinical and Research Reports|January 13, 2025
Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated TumorsAlissa J Cooper, Andrea Arfe, Biagio Ricciuti, et al.
JAMA Oncology|December 26, 2024
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung CancerMehrdad Rakaee, Masoud Tafavvoghi, Biagio Ricciuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLCGonzalo Recondo, Magda Bahcall, Liam F Spurr, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 30, 2022
Clinicopathologic and molecular spectrum of testicular sex cord-stromal tumors not amenable to specific histopathologic subclassificationStephanie E Siegmund, Lynette M Sholl, Harrison K Tsai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 20, 2025
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancerB Ricciuti, S Scalera, X Wang, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|December 27, 2019
Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver ConcordanceTheresa A Boyle, Farah K Khalil, Mari Mino-Kenudson, et al.
JAMA Oncology|May 22, 2025
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung CancerBiagio Ricciuti, Francesca Fusco, Alissa Cooper, et al.
Nature Communications|September 24, 2022
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitorsYoshihisa Kobayashi, Geoffrey R Oxnard, Elizabeth F Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2018
Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non-Small Cell Lung CancerMagda Bahcall, Mark M Awad, Lynette M Sholl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancersJ K Sabari, G C Leonardi, C A Shu, et al.
Pageof 32